课题基金 / 基金详情

Mississippi Diversity in Hypertension and Cardiorenal Research Program

Mississippi Diversity in Hypertension and Cardiorenal Research Program
密西西比州高血压和心肾研究计划的多样性
批准号:
10115781
负责人:
Joshua S Speed
金额:
$8.94万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
未结题
起止时间:
2014-04-01 至 2025-03-31

项目摘要

项目成果

Joshua S Speed的其他基金

相似基金

相关文献

中文摘要
翻译
密西西比州是心脏病、中风、高血压、糖尿病死亡率最高的州之一, 肾病密西西比也有最大的医疗保健差距在全国沿着与有限的 必要的校外研究支持,以招募和留住顶尖的生物医学研究人员,可以解决这些问题 重要问题。这些不断扩大的医疗保健差距影响到代表性不足的少数群体,包括非洲人, 美国人和西班牙裔美国人,谁是不成比例地受到心脏病,中风,糖尿病, 肾炎/肾病、高血压和高血压相关肾病。因此,一个独特的机会 存在于密西西比,用于建立多样化的研究基础设施,以研究机制和新的治疗方法 心血管和肾脏疾病在美国最突出的地方的选择 States.本申请建议继续在国家非常成功的夏季研究计划, 密西西比州增加了代表性不足的少数民族(URM)的个人参与, 高血压,肾脏和心血管相关的生物医学领域在过去五年。密西西比河 高血压和肾脏疾病研究计划(MSDHCR)的多样性支持了40多名URM学生 在第一个资助周期,超过90%的毕业生在研究生院利用他们的科学学位, 职业学校,或在其就业。密西西比大学医学中心(UMMC)有一个长期的 在心血管和肾脏研究方面的卓越历史,以及指导。目前的提案寻求 MSDHCR计划的额外五年,代表了使命的关键组成部分, 指导心血管和肾脏研究人员。这一竞争性更新包括加强机构 支持和创新的改进,以确保持续发展一个强大的生物医学管道。 该培训计划的总体目标是提供职业和教育指导,沿着国家的 艺术心血管和肾脏研究培训经验,以个人与弱势群体, 心血管和肾脏科学领域的种族或民族背景代表性不足。本科 来自弱势和代表性不足背景的学生将参加这个项目, 以下目标:1.为计划参与者提供多学科培训和指导经验, 心血管和肾脏研究。2.为计划参与者提供专业的机会, 发展,这将有助于他们实现在健康相关的研究专业的职业生涯。3.提供 为计划参与者提供标准化测试培训,为他们的教育课程的下一步做好准备。 训练
英文摘要
Mississippi is among the leaders in mortality due to heart disease, stroke, hypertension, diabetes mellitus, and kidney disease. Mississippi also has the greatest health care disparities in the country along with limited extramural research support necessary to recruit and retain top biomedical researchers that can address these important issues. These widening health care disparities affect underrepresented minorities, including African Americans and Hispanic Americans, who are disproportionately affected by heart disease, stroke, diabetes, nephritis/nephrosis, hypertension and hypertension related renal diseases. Therefore, a unique opportunity exists in Mississippi for building diverse research infrastructure to investigate mechanisms and new treatment options for cardiovascular and renal diseases at the very location where they are most prominent in the United States. This application proposes to continue a highly successful summer research program in the State of Mississippi that increased the participation of individuals from underrepresented minorities (URM) in hypertension, renal and cardiovascular related biomedical fields over the last five years. The Mississippi Diversity in Hypertension and Cardiorenal Research Program (MSDHCR) supported over forty URM students in the first funding cycle, with greater than 90% of graduates utilizing their science degree in graduate school, professional school, or in their employment. The University of Mississippi Medical Center (UMMC) has a long history of excellence in cardiovascular and renal research, and mentoring. The current proposal seeks an additional five years for the MSDHCR program, and represents a critical component of the mission to train and mentor cardiovascular and renal researchers. This competitive renewal includes enhanced institutional support and innovative improvements that ensure the continued development of a robust biomedical pipeline. The overall objective of this training program is to provide career and education mentoring along with state-of the art cardiovascular and renal research training experiences to individuals with disadvantaged and underrepresented ethnic or racial backgrounds in the cardiovascular and renal sciences. Undergraduate students from disadvantaged and underrepresented backgrounds will participate in this program that has the following aims: 1. To provide program participants a multi-disciplinary training and mentoring experience in cardiovascular and renal research. 2. To provide program participants with opportunities for professional development that will help them achieve careers in health-related research professions. 3. To provide standardized test training for program participants that will prepare them for the next steps in their educational training.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Endothelin-1 in Obesity and Insulin Resistance
Endothelin-1 in Obesity and Insulin Resistance
Endothelin-1 in Obesity and Insulin Resistance
Endothelin-1 in Obesity and Insulin Resistance
海外基金